DOCSLIB.ORG

Nutrition and Growth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nutrition and Growth J Clin Res Ped Endo 2009;1(4):157–163 ISSN: 1308-5727 DOI: 10.4274/jcrpe.v1i4.39 Online ISSN: 1308-5735 Nutrition and Growth Fima Lifshitz President, Pediatric Sunshine Academics, Inc; Director of Pediatrics & Senior Nutrition Scientist, Sansum Medical Research Institute, Santa Barbara, CA, USA and Professor of Pediatrics, Emeritus, Downstate Medical Center, State University of New York, Brooklyn, NY, USA; Former Professor of Pediatrics, Cornell University Medical College, New York, NY & University of Miami, Miami, FL, USA Keywords: ABSTRACT Nutritional growth retardation (NGR), nutrient intake, short stature, growth retardation, Nutrition plays a fundamental role in determining the growth of individuals. An appropri- metabolic rates, erythrocyte ate growth progression is considered a harbinger of adequate nutrient intake and good Na+,K+- ATPase activity. health. On the other hand growth deceleration with or without short stature may indicate inadequate nutrition, even when there is no body weight deficit for height. Nutritional growth Received: 11 November, 2008 Accepted: 04 December, 2008 retardation (NGR) is most prevalent in populations at risk of poverty. However in affluent com- munities patients with NGR are often referred to the specialist because of short stature and Corresponding Author: delayed sexual development. The diagnosis may be overlooked and/or be established after Fima Lifshitz exhaustive evaluations, if the pattern of weight progression over time is not considered. Pediatric Sunshine Academics, Inc. Director of Pediatrics & Patients with so-called idiopathic short stature may present diminished nutrient intake and Senior Nutrition Scientist decreased IGF-I levels, however their nutritional status and body weight progression patterns Sansum Medical Research are usually not addressed by pediatric endocrinologists. NGR patients may cease to gain Institute Santa Barbara, CA, appropriate weight and fail to grow in height, even without exhibiting body weight deficits USA Tel: +805-687 8038 for height. They adapt to decreased nutrient intake by decreasing growth progression and Fax: +805-682 3332 thereby achieve equilibrium by decreasing the nutrient demands. This occurs by diminishing E-mail: [email protected] their metabolic rates and erythrocyte Na+,K+- ATPase activity, however they may not present alterations in other clinical biochemical markers of malnutrition. Therefore accurate weights and heights plotted on the growth chart over time are necessary to detect NGR. Nutritional rehabilitation is accompanied with catch up growth, though it may be difficult to change the dietary habits of adolescents who exhibit NGR. Conflict of interest: None declared Growth is the fundamental physiologic time and compares it to expected norms. process that characterizes childhood. It The norms are usually provided by the gen- should be closely monitored by pediatri- eral population as depicted in growth charts cians and families alike as a benchmark of (www.cdc.gov/growthcharts).2 Short stature a child’s health. Similarly, secular trends in and growth failure frequently, but not growth patterns are followed as indicators always, occur together. For example, a of children’s health on a population level. healthy child of short parents will have Growth can be worrisome along two vari- short stature but not growth failure; he or ables: height (short stature) and velocity she will grow at normal velocity towards a (growth failure).1 Height involves a meas- lower genetic potential. Conversely, a REVIEW urement of linear stature at a single point in child of very tall parents can have growth © 2008 Journal of Turkish Pediatric Endocrinology and Diabetes Society This is an open-access article distributed under the terms of the 157 Pubbiz/Probiz Ltd. fiti. Creative Commons Attiribution License which permits unrestricted use distribution and reprodiction in any medium prov ided the original work is prope rly cited Nutrition and Growth failure, but still be taller than the cut-off for be over-emphasized, carefully assessing the short stature of the general population. progression of body weight is equally rele- Multiple diseases can present solely with vant to be able to recognize NGR. growth failure, not necessarily with short Longitudinal assessment of both height and stature. Included are non-endocrine diseases weight is required.6-9 i.e. as celiac disease, cystic fibrosis, renal An increasing number of children on disease and HIV infection.1 These alterations stimulant medications are being referred to share a common pathophysiological process the pediatric endocrinologist for short stature in regards to growth failure, namely malnu- evaluation. Stimulant medication for the trition. Non organic causes leading to treatment of attention deficit hyperactivity decreased food intake may also result in disorder (ADHD) has long been suspected of poor growth and short stature. Failure to adversely affecting linear growth, since it is asses a patients’ nutritional intake can lead well known that these medications produce to unnecessarily delayed or missed NGR anorexia and poor nutrient intake. A cooper- diagnoses. The clinical outcome of many ative growth paper reviewed 29 cohort stud- nutritional alterations depends on the timeli- ies of children treated with methylphenidate ness of diagnosis and treatment.3,4 or dexamphetamine.10 The most sensitive The single most important cause of studies measured growth progression before growth retardation worldwide is poverty- and after the period of treatment, and eight related malnutrition. When suboptimal nutri- of these 16 studies showed an attenuation of tion is continued for prolonged periods of growth on stimulants. In the most rigorous time, growth stunting occurs as the main study, 540 children, 7-9 yr old, with ADHD clinical phenotype.3,4 However nutritional were randomly assigned to different treat- growth retardation (NGR) is a frequently ment groups for up to 24 months. The under-appreciated entity in pediatric behavioral effectiveness of medication use endocrine practices in the United States. was greatest among children who ingested Poverty-related malnutrition is less common medications throughout the 24-month obser- than in developing nations, and if anything, vation period. Those who stopped taking the current major health crisis is the obesity their medication and those who did not epidemic. Partly in response to the obesity ingest them consistently showed increasing around them, a subset of American youths, behavioral problems. However, there was many from suburban upper middle class, significant growth deterioration among chil- restrict their nutrient intake and develop dren who took the medication for the NGR and delayed sexual development.1 This longest periods. After 2 years’ treatment, decreased intake is on the continuum of height was suppressed by a mean of –1.94 weight gain problems; it is insufficient to cm and deficits in weight gain were even support normal growth but it does not larger. The authors concluded that consistent include a distorted body image as occurs in treatment with stimulant medication was eating disorders.5 associated with maintenance of behavioral Children with NGR are generally referred effectiveness but continued growth suppres- to the pediatric endocrinologist because of sion.11 The somewhat larger deterioration short stature or delayed puberty. Therefore, observed in body weight may be due to the pediatricians and pediatric endocrinologists anorexic effects of these medications. need to recognize NGR and become familiar Suboptimal nutrition appears to be an under- with its causes and treatment. Although the lying cause of stimulant-mediated growth fal- importance of evaluating the pattern of tering. stature increments throughout life in the The classic anthropometric criteria for differential diagnosis of short stature cannot NGR stipulate low weight for age with min- 158 © 2009 Journal of Turkish Pediatric Endocrinology and Diabetes Society Lifshitz F. imal deficits in weight for height. By these retinol-binding protein, pre-albumin, albu- cross-sectional criteria, it may be difficult to min, transferrin, and triiodothyronine (T3) differentiate NGR children from those with levels, do not differentiate NGR patients familial short stature or constitutional from those with familial or constitutional growth delay.6-9 Only the longitudinal pro- short stature. Other indices of malnutrition, gression of body weight and height can such as the urinary creatine-height index or more clearly reveal NGR, which may occur urinary nitrogen/creatinine ratio, do not usu- even when there is weight-for-height ally demonstrate abnormalities. The reason excess.12 The distinguishing feature is a is that NGR patients have adapted to their delay in linear growth and puberty resulting suboptimal nutritional intake and they main- from inadequate weight gain. Thus, tain homeostasis by decreasing growth, although concern is intensified when weight thereby reaching equilibrium with preserva- or height measurements fall below the 5th tion of biochemical nutritional markers.13 percentile, growth failure expressed as dete- Although fasting and protein-calorie mal- rioration across percentiles of weight and nutrition have been shown to lower circulat- height may also indicate NGR even when ing IGF-I levels in humans and rodents, the child is still above the 5th percentile. IGF-I levels may not differentiate NGR With nutritional rehabilitation, catch-up patients from those
Load more

Recommended publications
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in A
    Program Nr: 1 from the 2004 ASHG Annual Meeting Mutations in a novel member of the chromodomain gene family cause CHARGE syndrome. L.E.L.M. Vissers1, C.M.A. van Ravenswaaij1, R. Admiraal2, J.A. Hurst3, B.B.A. de Vries1, I.M. Janssen1, W.A. van der Vliet1, E.H.L.P.G. Huys1, P.J. de Jong4, B.C.J. Hamel1, E.F.P.M. Schoenmakers1, H.G. Brunner1, A. Geurts van Kessel1, J.A. Veltman1. 1) Dept Human Genetics, UMC Nijmegen, Nijmegen, Netherlands; 2) Dept Otorhinolaryngology, UMC Nijmegen, Nijmegen, Netherlands; 3) Dept Clinical Genetics, The Churchill Hospital, Oxford, United Kingdom; 4) Children's Hospital Oakland Research Institute, BACPAC Resources, Oakland, CA. CHARGE association denotes the non-random occurrence of ocular coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear anomalies and deafness (OMIM #214800). Almost all patients with CHARGE association are sporadic and its cause was unknown. We and others hypothesized that CHARGE association is due to a genomic microdeletion or to a mutation in a gene affecting early embryonic development. In this study array- based comparative genomic hybridization (array CGH) was used to screen patients with CHARGE association for submicroscopic DNA copy number alterations. De novo overlapping microdeletions in 8q12 were identified in two patients on a genome-wide 1 Mb resolution BAC array. A 2.3 Mb region of deletion overlap was defined using a tiling resolution chromosome 8 microarray. Sequence analysis of genes residing within this critical region revealed mutations in the CHD7 gene in 10 of the 17 CHARGE patients without microdeletions, including 7 heterozygous stop-codon mutations.
    [Show full text]
  • Blueprint of Pediatric Endocrinology Book
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/317428263 blueprint of pediatric endocrinology book Book · January 2014 CITATIONS READS 0 27 1 author: Abdulmoein Eid Al - Agha King Abdulaziz University 148 PUBLICATIONS 123 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: HYPOPHOSPHATEMIC RICKETS, EPIDERMAL NEVUS SYNDROME WITH... View project HYPERTRIGLYCERIDAEMIA-INDUCED ACUTE PANCREATITIS IN AN INFANT: A CASE REPORT View project All content following this page was uploaded by Abdulmoein Eid Al - Agha on 09 June 2017. The user has requested enhancement of the downloaded file. IN THE NAME OF ALLAH, THE MERCIFUL, THE MERCY-GIVING iii Blueprint in Pediatric Endocrinology Abdulmoein Eid Al-Agha, MBBS, DCH, FRCPCH Pediatric Endocrinologist King AbdulAziz University Faculty of Medicine Jeddah, Saudi Arabia © King Abdulaziz University: 1435 A.H. (2014 AD.) All rights reserved. 1st Edition: 1435 A.H. (2014 A.D.) Table of Contents Chapter 1: Basic Endocrinology Introduction…………………………………………………………………….. 3 Effects of hormones…………………………………………………………….. 3 Types of hormones……………………………………………………………… 4 Types of Hormone Receptors………………...………………………………... 5 Loss – of – function mutations………………………………………………….. 7 Gain – of – function mutations……………………………...………………….. 9 Fetal Brain Programming ………………………………………………………. 10 The endocrine system ……………………………...…………………………... 10 Hypothalamic-Pituitary Relationships………………………………………….. 10 Hypothalamic Controls………………………………………………………….
    [Show full text]
  • Childhood Growth and Puberty Delay Disorders
    Childhood Growth and Puberty Delay Disorders MAJ Craig Barstow, MD ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations. The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP. 1 DISCLOSURE It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
    [Show full text]
  • Incorrect Unit of Measure
    We agree with Berman that there may often be honest dif- (2) make the rationale public, and (3) provide opportunities for ferences of opinion among informed experts about the value of clinicians and members to appeal policies and specific deci- new treatments. As stated in our article, our study cannot sions.1 However, even in the outstanding programs we were establish whether current practices are right or wrong. How- privileged to study in our research on policymaking, we and ever, the wide gap between the recommendations of physi- the program leaders agreed there was room for significant cians and the approvals of insurers in the cases under study improvement. underscores a potentially far-reaching problem in the US Ms Tesch’s letter on behalf of the Turner’s Syndrome Soci- health care system. We believe that insurers often make very ety provides an example of well-conceived advocacy. The fact careful and fair analyses of information in arriving at coverage that GH has been recognized by the Food and Drug Admin- decisions.1 Nevertheless, greater dialogue between insurers istration as effective in the treatment of Turner syndrome and physicians is needed to minimize discrepancies in cover- puts a burden of explanation onto an insurer who chooses not age and to provide optimal patient care. to cover it. In asking whether decisions to deny coverage re- Dr Yaes asks about consensus among physicians for the flect “reasonable cost-benefit analysis or an inappropriate de- cases studied and about the value of a treatment such as GH, nial of care,” Tesch raises the key policy question in useful which is used for a non–life-threatening condition.
    [Show full text]
  • Guideline for the Diagnosis and Treatment of Celiac
    JOBNAME: gas 40#1 2005 PAGE: 1 OUTPUT: Wed December 15 18:39:15 2004 lww/gas/84141/MPG157309 Prod #: MPG157309 MS #xxx Journal of Pediatric Gastroenterology and Nutrition 40:1–19 Ó January 2005 Lippincott Williams & Wilkins, Philadelphia Clinical Guideline Guideline for the Diagnosis and Treatment of Celiac Disease in Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition ABSTRACT The Committee examined the indications for testing, the value Celiac disease is an immune-mediated enteropathy caused by of serological tests, human leukocyte antigen (HLA) typing and a permanent sensitivity to gluten in genetically susceptible in- histopathology and the treatment and monitoring of children dividuals. It occurs in children and adolescents with gastroin- with celiac disease. It is recommended that children and ado- testinal symptoms, dermatitis herpetiformis, dental enamel lescents with symptoms of celiac disease or an increased risk defects, osteoporosis, short stature, delayed puberty and persis- for celiac disease have a blood test for antibody to tissue tent iron deficiency anemia and in asymptomatic individuals transglutaminase (TTG), that those with an elevated TTG be with type 1 diabetes, Down syndrome, Turner syndrome, Williams referred to a pediatric gastroenterologist for an intestinal biopsy syndrome, selective immunoglobulin (Ig)A deficiency and first and that those with the characteristics of celiac disease on degree relatives of individuals with celiac disease. The Celiac intestinal histopathology be treated with a strict gluten-free Disease Guideline Committee of the North American Society diet. This document represents the official recommendations of for Pediatric Gastroenterology, Hepatology and Nutrition has the North American Society for Pediatric Gastroenterology, formulated a clinical practice guideline for the diagnosis and Hepatology and Nutrition on the diagnosis and treatment of treatment of pediatric celiac disease based on an integration of celiac disease in children and adolescents.
    [Show full text]
  • Children with Idiopathic Short Stature Are Poor Eaters and Have Decreased Body Mass Index
    Children With Idiopathic Short Stature Are Poor Eaters and Have Decreased Body Mass Index Stefan A. Wudy*; Sandra Hagemann, MD*; Astrid Dempfle, PhD‡; Gundula Ringler, MSC‡; Werner F. Blum*§; Lars D. Berthold, MD࿣; Gerhard Alzen࿣; Ludwig Gortner¶; and Johannes Hebebrand# ABSTRACT. Objective. In children with idiopathic s.org/cgi/doi/10.1542/peds.2004-1684; eating behavior, short stature (ISS), studies investigating body mass index short stature, body mass index, leptin, ghrelin. (BMI) or parameters of satiety regulation are scarce, and studies analyzing eating behavior are lacking. Methods. We recruited 214 children (123 index cases ABBREVIATIONS. CDGP, constitutional delay of growth and and 91 siblings) with ISS from 123 families. Affected puberty; FSS, familial short stature; ISS, idiopathic short stature; IGF-I, insulin-like growth factor I; IGFBP-3, insulin-like growth children had to have a body height <5th percentile, or, in factor–binding protein 3; CEBQ, Child Eating Behavior Question- the case of siblings, the body height of 1 child had to be naire; SDS, standard deviation score; LFFQ, Leeds Food Fre- <5th percentile and the other <15th percentile. Medical quency Questionnaire. histories were recorded by using structured and stan- dardized interviews. Eating behavior was assessed by using the Child Eating Behavior Questionnaire. Percent hort stature is the most common cause for re- energy intake as fat was assessed by using the Leeds ferrals to pediatric endocrinologists. Many of Food Frequency Questionnaire. Endocrine markers of these patients have no identifiable medical ab- body weight regulation (leptin, ghrelin) were determined S normality and are classified with diagnoses such as in serum.
    [Show full text]
  • Short Stature in Childhood — Challenges and Choices
    T h e new england journal o f medicine clinical practice Short Stature in Childhood — Challenges and Choices David B. Allen, M.D., and Leona Cuttler, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors’ clinical recommendations. From the Division of Pediatric Endocri- A family seeks evaluation and treatment of short stature in their 11.5-year-old son. He nology and Diabetes, American Family previously was in the 3rd percentile for height, but his growth rate has slowed during Children’s Hospital, University of Wis- consin School of Medicine and Public the past 2 years, and his height is now just below the 1st percentile (Fig. 1). His moth- Health, Madison (D.B.A.); and the Center er is 5 ft 0 in. (152 cm), and his father is 5 ft 6 in. (167 cm). The child’s size at birth was for Child Health and Policy and the Divi- normal. His medical history and a review of systems are unremarkable. His physical sion of Endocrinology and Diabetes, Rainbow Babies and Children’s Hospital, examination is normal and shows prepubertal development. The complete blood count, Case Western Reserve School of Medi- erythrocyte sedimentation rate, thyrotropin, tissue transglutaminase antibody, and cine, Cleveland (L.C.). Address reprint insulin-like growth factor I (IGF-I) levels and growth hormone levels after provoca- requests to Dr. Allen at the University of Wisconsin School of Medicine and Public tive testing are normal.
    [Show full text]
  • Prevalence of Short Stature and Malnutrition Among Egyptian Primary School Children and Their Coexistence with Anemia Ali M
    El-Shafie et al. Italian Journal of Pediatrics (2020) 46:91 https://doi.org/10.1186/s13052-020-00855-y RESEARCH Open Access Prevalence of short stature and malnutrition among Egyptian primary school children and their coexistence with Anemia Ali M. El-Shafie1 , Zeinab A. Kasemy2 , Zein A. Omar1 , Safa H. Alkalash3, Amal A. Salama3, Kerollos S. Mahrous1,4* , Shaimaa M. Hewedy5, Nessreen M. Kotb5, Heba S. Abd El-Hady5, Eman S. Eladawy5, Mohamed A. Zeid5, Manar E. Abd El Hamid5, Emad H. Hemeda5, Mohamed A. El-shafie5, Esraa A. El-Meligy5 and Wael A. Bahbah1 Abstract Background: Under nutrition and overweight typically occur during nutritional transition periods in developing countries including Egypt. Short stature and anemia are public health concern due to its strong link with malnutrition which is a preventable risk factor. Objectives: to estimate the prevalence of overweight, obesity, underweight and short stature and its concurrence with anemia, also to determine the etiological profile of short stature among primary school children in Egypt. Methods: A cross-sectional study was carried out on 33,150 Egyptian children aged 6–11 years old from January 2018 to January 2020, allocated in 59 primary schools from diverse geographical districts in Egypt. Complete anthropometric measurements were conducted and applied according to WHO growth charts. Hemoglobin level was measured. Systematic approach to detect the etiology of short stature was applied randomly to a sample of 380 stunted children. Results: The prevalence of underweight was 8.2%, while obesity and overweight represented 21.8% (9.6 and 12.2% respectively). Overall short stature constituted 17%.
    [Show full text]
  • Causes of Short Stature Author: Alan D Rogol, MD, Phd Section Editors
    Causes of short stature Author: Alan D Rogol, MD, PhD Section Editors Peter J Snyder, MD Mitchell Geffner, MD Deputy Editor Alison G Hoppin, MD Contributor disclosures All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Mar 2016. | This topic last updated: Aug 13, 2015. INTRODUCTION — Short stature is a term applied to a child whose height is 2 standard deviations (SD) or more below the mean for children of that sex and chronologic age (and ideally of the same racial-ethnic group). This corresponds to a height that is below the 2.3rd percentile. Short stature may be either a variant of normal growth or caused by a disease. The most common causes of short stature beyond the first year or two of life are familial (genetic) short stature and delayed (constitutional) growth, which are normal non-pathologic variants of growth. The goal of the evaluation of a child with short stature is to identify the subset of children with pathologic causes (such as Turner syndrome, inflammatory bowel disease or other underlying systemic disease, or growth hormone deficiency). The evaluation also assesses the severity of the short stature and likely growth trajectory, to facilitate decisions about intervention, if appropriate. This topic will review the main causes of short stature. The diagnostic approach to children with short stature is discussed separately. (See "Diagnostic approach to children and adolescents with short stature".) NORMAL VARIANTS OF GROWTH Familial short stature — Familial or genetic short stature is most often a normal variant, termed familial or genetic short stature (figure 1).
    [Show full text]
  • Growth Hormone [Somatropin]
    Cigna National Formulary Coverage Policy Prior Authorization Growth Disorders - Growth hormone [somatropin] Table of Contents Product Identifer(s) National Formulary Medical Necessity ................ 1 12988 Conditions Not Covered....................................... 8 Background ........................................................ 10 References ........................................................ 14 Revision History ................................................. 16 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Endocrinology
    THE AMERICAN BOARD OF PEDIATRICS® CONTENT OUTLINE Pediatric Endocrinology Subspecialty In-Training, Certification, and Maintenance of Certification (MOC) Examinations INTRODUCTION This document was prepared by the American Board of Pediatrics Subboard of Pediatric Endocrinology for the purpose of developing in-training, certification, and maintenance of certification examinations. The outline defines the body of knowledge from which the Subboard samples to prepare its examinations. The content specification statements located under each category of the outline are used by item writers to develop questions for the examinations; they broadly address the specific elements of knowledge within each section of the outline. Pediatric Endocrinology Each Pediatric Endocrinology exam is built to the same specifications, also known as the blueprint. This blueprint is used to ensure that, for the initial certification and in-training exams, each exam measures the same depth and breadth of content knowledge. Similarly, the blueprint ensures that the same is true for each Maintenance of Certification exam form. The table below shows the percentage of questions from each of the content domains that will appear on an exam. Please note that the percentages are approximate; actual content may vary. Initial Maintenance Certificatio of Content Categories n and Certification In-Training (MOC) 1. Carbohydrate Metabolism 16% 16% 2. Bone and Mineral Metabolism 8% 8% Thyroid Hormones (Thyroxine 3. [T4] and Triiodothyronine [T3]) 13% 14% 4. Adrenal Disorders 12% 12% 5. Pituitary/Hypothalamus 10% 10% 6. Growth 12% 14% 7. Reproductive Endocrine System 12% 12% 8. Other Hormones 3% 3% 9. Lipoproteins and Lipids 3% 3% Multiple endocrine neoplasia and 10. polyglandular autoimmune disease 2% 2% 11.
    [Show full text]